TOLREMO therapeutics

TOLREMO therapeutics is a biotechnology and pharmaceutical company headquartered in Switzerland, founded in 2017. The company's mission revolves around preventing non-genetic cancer drug resistance by dismantling the earliest defense to targeted therapies. Their approach is led by phenotypic insights, leading to the discovery of a pivotal mechanism that governs critical transcriptional resistance pathways. Their clinical compound TT125-802 is an orally available small molecule inhibitor designed to block these survival techniques, aiming to significantly improve the response rates and durability of established treatments. Their slogan, Stopping non-genetic cancer drug resistance as it emerges, encapsulates the essence of their work.

The company recently secured Fr.3.41M Series A investment on 20 September 2023, with participation from BioMed Partners and Pierre Fabre Invest. This investment signifies confidence from notable investors in the potential of TOLREMO therapeutics to address a universal challenge for current and future targeted therapies, ultimately leading to lasting patient benefits.